AGENDA

1. **Standing business**
   - Welcome & apologies
   - Declaration of potential or actual Conflict of Interest
   - Correspondence
   - Update from Secretariat

2. **Reviews of existing LSDP medicines**
   - **TRANCHE 1**
     - Consideration of Fabry disease medicines final report
     - Consideration of Gaucher disease medicines draft report
   - **TRANCHE 2 – consideration of draft reports**
     - Idursulfase (Elaprase®) for treatment of Mucopolysaccharidosis type II
     - Alglucosidase alfa (Myozyme®) for treatment of Pompe disease
     - Eculizumab (Soliris®) for treatment of Paroxysmal Nocturnal Haemoglobinuria
   - **TRANCHE 3 – updates**
     - Laronidase (Aldurazyme®) for treatment of Mucopolysaccharidosis type I
     - Galsulfase (Naglazyme®) for treatment of Mucopolysaccharidosis type VI
     - Nitisinone (Orfadin®) for Hereditary Tyrosinaemia type I

3. **Applications for new LSDP medicines**

4. **Other business**